Some patients fear tirzepatide, sold by Eli Lilly under the brand names Zepbound and Mounjaro, will be hard to get and prohibitively expensive once compounding pharmacies are no longer producing it.

Researchers find tirzepatide more effective than semaglutide for weight loss in a 72-week trial, with significant reductions in body weight and waist circumference.

A three-year study of tirzepatide – a medication approved in the US as Mounjaro for diabetes and Zepbound for weight loss – found that when adults who had prediabetes and obesity or overweight ...

But what is compounded tirzepatide? Compounded tirzepatide is a formulation of tirzepatide that’s been changed in some way from the FDA-approved versions of the drug.

Tirzepatide, sold under the brand names Zepbound and Mounjaro, is a prescription medication that works for weight loss by reducing appetite and increasing satiety. Administered as a once-weekly ...

A head-to-head trial found that tirzepatide led to significantly greater weight loss and waist reduction than semaglutide in adults with obesity but without diabetes. Over 72 weeks, tirzepatide ...

Adults with type 2 diabetes receiving tirzepatide had significantly greater declines in urine albumin-to-creatinine ratio than those receiving comparators such as placebo or another therapy ...

People with obesity and prediabetes assigned tirzepatide were more likely to have sustained weight loss than those assigned placebo. Most people on tirzepatide sustained weight loss through 176 weeks.

Tirzepatide and semaglutide are type 2 diabetes drugs that are often used for weight loss. While tirzepatide may potentially be more effective, it's too early to know that based on current research.

Switch to Tirzepatide in T2D More Effective Than Upping Dulaglutide Dose — Patients who switched had greater reductions in HbA1c and weight ...

SUMMT has shown for the first time that a drug can reduce major heart failure clinical outcomes in patients with heart failure and a preserved ejection fraction and obesity.

Some patients fear that they’ll lose access to tirzepatide because the US Food and Drug Administration determined that a shortage of the brand-name drug has ended – which means compounding of ...